<DOC>
	<DOCNO>NCT00978120</DOCNO>
	<brief_summary>The purpose study assess safety body 's immune response ( body 's defense disease ) experimental H1N1 influenza vaccine people asthma . The study enroll 350 , possibly 400 healthy adult age 12 old mild , moderate , severe asthma . Participants randomly assign 1 2 possible vaccine group : group 1 receive 15 mcg H1N1 vaccine ; group 2 receive 30 mcg H1N1 vaccine give two 15 mcg injection . Both group receive vaccine injection day 0 21 . Study procedure include : medical history , physical exam , spirometry , maintain memory aid , blood sample collection . Participants involve study related procedure approximately 7 month .</brief_summary>
	<brief_title>Safety Efficacy H1N1 Influenza Vaccine People With Asthma</brief_title>
	<detailed_description>A new swine-origin influenza A/H1N1 virus recently identify significant cause respiratory illness Mexico United States . In response , World Health Organization ( WHO ) declare pandemic June 11 , 2009 . Current data indicates license seasonal influenza vaccine likely provide protection new H1N1 virus . Development deployment vaccine new H1N1 virus , particularly at-risk population , essential . Groups risk influenza yearly include elderly asthma , current guideline Advisory Committee Immunization Practices ( ACIP ) recommend vaccination adult child asthma . Early , unpublished data US patient hospitalize H1N1 infection indicate many underlie asthma , expect people asthma priority list H1N1 influenza vaccination . Data also indicate increase dosage vaccine may increase development antibody use certain inhaler may affect immunization . This study test safety immunogenicity unadjuvanted , inactivated H1N1 vaccine two dosage level people asthma . Participation study last approximately 34 week . Participants stratify two group : mild moderate versus severe asthma . All participant randomly assign receive either high dose ( 30 mcg ) low dose ( 15 mcg ) H1N1 vaccine . Both vaccine dosage administer two intramuscular injection 21 day apart . Participants assign high dose ( 30 mcg ) receive two injection 15 mcg vaccine administration . Participants complete study visit entry , administration vaccine Days 1 21 , follow-ups week vaccine injection , 21 day second injection . Measurements visit include spirometry ( measurement air enter leave lung ) , questionnaire asthma , target physical examination , adverse event medication assessment , inspection vaccination site , collection blood sample . A urine sample collect pregnancy test vaccination . In addition , 8 day vaccination injection participant keep diary record oral temperature , adverse event , asthma symptom , use inhaler . These diary review study visit . Participants also receive follow-up phone call assess safety 60 , 120 , 180 day last vaccine injection .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Diagnosis mild/moderate severe asthma accord Severe Asthma Research Project ( SARP ) definition either SARP participant prior participation study clinics investigator Males females age 12 ( inclusive ) old Females childbearing potential must pregnant must agree practice adequate contraception may include , limited : abstinence , monogamous relationship vasectomize partner , barrier method condom , diaphragm , spermicide , intrauterine device , license hormonal method study least 30 day follow last vaccination . Able understand comply plan study procedure Will provide write informed consent assent ( age appropriate ) prior initiation study procedure Allergy egg component vaccine , include gelatin , formaldehyde , octoxinol , thimerosal , chicken protein Positive urine pregnancy test within 24 hour prior vaccination , female childbearing potential Currently breastfeed History smoke 20 packyears great ( current former smoker history le 20 packyears include study ) Has previously diagnose physician chronic obstructive pulmonary disease , chronic bronchitis , emphysema , cystic fibrosis Has receive anticancer chemotherapy radiation therapy ( cytotoxic ) within past 36 month Has active neoplastic disease history hematologic malignancy Has diagnosis schizophrenia , bipolar disease , major psychiatric diagnosis Has hospitalize psychiatric illness , history suicide attempt , confinement danger self others within past 10 year Receiving psychiatric drug ( subject receive single antidepressant drug stable least 3 month prior study entry , without decompensating symptom , allow enroll ) History receive immunoglobulin , include anticytokine antibody , blood product within 3 month prior vaccination study Has receive experimental agent ( vaccine , drug , biologic , device , blood product , medication ) within 1 month prior vaccination study expect receive experimental agent study ( prior Day 141 followup call 100 day second vaccination ) Has receive live license vaccine within 4 week inactivate licensed vaccine within 2 week prior vaccination study , plan receipt vaccine within 21 day follow second vaccination Has history severe reaction follow previous immunization influenza virus vaccine Has acute illness , include oral temperature great 100.4°F , within 1 week either vaccination Has chronic neurologic autoimmune disorder Has history GuillainBarré Syndrome Has acute chronic medical condition , opinion investigator , would render vaccination unsafe , would interfere evaluation vaccine response Has ongoing asthma exacerbation asthma exacerbation resolve less 7 day prior vaccination Has condition would , opinion site investigator , place participant unacceptable risk injury , render participant unable meet requirement protocol , interfere successful completion study . Participated novel influenza H1N1 2009 vaccine study past two year history novel influenza H1N1 2009 infection treatment Has know active HIV , Hepatitis B Hepatitis C infection Has history alcohol drug abuse last 5 year Plans travel outside North America time first vaccination 42 day follow first vaccination Does speak English primarily</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Influenza A Virus , H1N1 Subtype</keyword>
	<keyword>Vaccine</keyword>
</DOC>